<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38796311</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0828</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of internal medicine</Title><ISOAbbreviation>Eur J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Multi-organ abnormalities assessed by a single MRI scan in individuals with blood cancer.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>152</EndPage><MedlinePgn>150-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejim.2024.05.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0953-6205(24)00230-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During the COVID-19 pandemic individuals with all blood cancers were classified as clinically vulnerable and at high risk of complications and death. Our study sought to determine if individuals with specific blood cancers were at a heightened risk of longer term organ impairment, secondary to SARS-CoV-2 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We set up a prospective observational study, utilising quantitative multi-parametric MRI to determine organ health over time in patients with specific blood cancers who had recovered from COVID-19.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Multi-organ abnormality was more prevalent in blood cancer patients than in healthy controls (42 % vs 6 % p &lt; 0.001) but comparable to the long COVID controls (42 % vs 33 %, p &gt; 0.05). At 6 month follow up scans, organ abnormalities persisted in most individuals with blood cancer (71 % &#x2265;1 organ and 52 % multi-organ).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A multi-organ MRI platform offers the capacity to accurately evaluate organ health dynamically in blood cancers and detect asymptomatic organ impairment. The application of multi-organ MRI could aid early detection and longitudinal monitoring of organ impairment, potentially guiding more personalised treatment strategies and improving clinical outcomes in many rare diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals' NHS Foundation Trust, Oxford, UK; Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pansini</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals' NHS Foundation Trust, Oxford, UK; Clinica Di Radiologia EOC, Istituto Di Imaging Della Svizzera Italiana (IIMSI), Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Charlie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Perspectum Ltd, Gemini One, 5520 John Smith Drive, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK; Department of Cardiology, University College London Hospitals NHS Foundation Trust, London, UK; Department of Cardiology, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomaides Brears</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Perspectum Ltd, Gemini One, 5520 John Smith Drive, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Onima</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals' NHS Foundation Trust, Oxford, UK; Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK. Electronic address: onima.chowdhury@ndcls.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Intern Med</MedlineTA><NlmUniqueID>9003220</NlmUniqueID><ISSNLinking>0953-6205</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of competing interest MP: Perspectum Ltd: Current Employment as Consultant, Current equity holder in private company. CD: Perspectum Ltd: Current Employment. HTB: Perspectum Ltd: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38796311</ArticleId><ArticleId IdType="doi">10.1016/j.ejim.2024.05.025</ArticleId><ArticleId IdType="pii">S0953-6205(24)00230-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>